CytoMed Therapeutics (GDTC) said Friday it received a Nasdaq notice Tuesday stating that the closing bid price of its ordinary shares had remained below the $1 minimum bid price requirement for 30 consecutive business days.
The company has 180 calendar days, or until April 5, 2027, to regain compliance with the requirement.
CytoMed said it plans to take measures to regain compliance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.